A5102026722- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- Polyomavirus and related diseases
- T-cell and Retrovirus Studies
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Lung Cancer Research Studies
- Histiocytic Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Eosinophilic Disorders and Syndromes
- Human Rights and Immigration
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Vector-Borne Animal Diseases
- Cardiac tumors and thrombi
- Pancreatic and Hepatic Oncology Research
- Cancer therapeutics and mechanisms
- Comparative constitutional jurisprudence studies
University of Miami
2016-2025
Sylvester Comprehensive Cancer Center
2014-2024
Palmetto Hematology Oncology
2013
City Of Hope National Medical Center
2012
Montefiore Medical Center
2012
University of Southern California
2012
Los Angeles Medical Center
2012
Memorial Sloan Kettering Cancer Center
2012
Albert Einstein College of Medicine
2012
City of Hope
2012
Abstract EBV-encoded microRNAs (miRNAs) have been identified and their functions are being studied. The expression pattern of these miRNAs in clinical samples EBV-associated non–Hodgkin's lymphomas is unknown. We analyzed five primary “endemic” pediatric Burkitt's (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a III line, three EBV+ effusion (PEL), AIDS-related diffuse large B-cell (DLBCL) for miRNAs. A markedly elevated miRNA BHRF1-3 relative to its...
Abstract Burkitt lymphoma (BL) accounts for most pediatric non-Hodgkin lymphomas, being less common but significantly more lethal when diagnosed in adults. Much of the knowledge genetics BL thus far has originated from study (pBL), leaving its relationship to adult (aBL) and other lymphomas not fully explored. We sought thoroughly identify somatic changes that underlie lymphomagenesis aBL any molecular features associate with clinical disparities within between pBL aBL. Through comprehensive...
Primary effusion lymphoma (PEL) is an aggressive B-cell most commonly diagnosed in HIV-positive patients and universally associated with Kaposi's sarcoma-associated herpesvirus (KSHV). Chemotherapy treatment of PEL yields only short-term remissions the vast majority patients, but efforts to develop superior therapeutic approaches have been impeded by lack animal models that accurately mimic human disease. To address this issue, we developed a direct xenograft model, UM-PEL-1, transferring...
Primary effusion lymphoma (PEL) is a rare form of aggressive B cell caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there an urgent need for new PEL therapies. Previously, we established, direct xenograft model PEL-bearing immune-compromised mice, that treatment with the proteasome inhibitor, bortezomib (Btz), increased survival relative to after doxorubicin. Herein, demonstrate combination Btz histone deacetylase...
<title>Abstract</title> Kaposi sarcoma (KS) is an AIDS-defining cancer and a significant global health challenge caused by KS-associated herpesvirus (KSHV). NGS-based approaches have profiled KS lesions in minimal number of studies compared with other neoplastic diseases. Here we present compiled harmonized dataset 131 non-tumor cutaneous samples the context their predicted pathway activities, immune infiltrate, KSHV HIV gene expression profiles, associated clinical data representing patient...
Although immunotherapy has emerged as a therapeutic strategy for many cancers, there are limited studies establishing the safety and efficacy in people living with HIV (PLWH) cancer.
Infusional chemotherapy is efficacious in patients with AIDS-related lymphoma, but it may be difficult to administer. We studied standard agents rituximab plus pegylated liposomal doxorubicin (DR-COP) an attempt provide a more practical approach therapy while ascertaining rates of response, potential infectious complications, and prognostic role biologic markers.We conducted prospective, multi-institutional phase II trial, employing (day 1) 40 mg/m(2), 375 cyclophosphamide 750 vincristine...
<h3>Background</h3> Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs HIV infected patients as they traditionally been excluded from CPIs clinical trials. <h3>Case presentation</h3> We present a case an HIV-positive patient with extensive extrapulmonary high-grade small cell carcinoma who was treated dual (nivolumab ipilimumab) complete response to therapy manageable profile. performed...
Approximately 12% of all human cancers worldwide are caused by infections with oncogenic viruses. Kaposi's sarcoma herpesvirus/human herpesvirus 8 (KSHV/HHV8) is one the viruses responsible for cancers, including Kaposi’s (KS), Primary Effusion Lymphoma (PEL), and lymphoproliferative disorder multicentric Castleman’s disease (MCD). Chronic inflammation mediated KSHV infection plays a decisive role in development survival these cancers. NF-κB, family transcription factors regulating...
No comparative studies exist for relapsed/refractory (rel/rfr) acquired immune deficiency syndrome (AIDS)-related lymphoma (ARL). To determine practices over the last decade and to assess outcomes of salvage chemotherapy with curative intent autologous stem cell transplant (ASCT), we retrospectively evaluated treatment in patients rel/rfr ARL who were treated 13 national AIDS Malignancy Consortium (AMC) sites between 1999 2008 (n = 88). The most commonly used second-line therapies ICE...
Treatment of Epstein–Barr virus (EBV)-related lymphomas with lytic-inducing agents is an attractive targeted approach for eliminating virus-infected tumor cells. Zidovudine (AZT) excellent substrate EBV-thymidine kinase: it can induce EBV lytic gene expression and apoptosis in primary EBV+ lymphoma cell lines. We hypothesized that the combination AZT chemotherapy would be effective treating lymphomas. report a retrospective analysis 19 patients aggressive non-Hodgkin lymphoma, including nine...
We studied the presence of Kaposi sarcoma herpesvirus sequences in cell-free DNA (cfDNA) isolated from blood patients with AIDS-related (KS) and primary effusion lymphoma (PEL). The use paramagnetic beads linked to methyl-CpG binding domain protein allowed separation virion cell-derived DNA. Only was detected KS patients, whereas a patient PEL. difference origins cfDNA these settings may part reflect very different proliferative indices PEL tumor tissue.
The nuclear factor kappa B (NFκB) pathway is essential for many human cancers. Therapeutics such as bortezomib (Velcade™) that interfere with NFκB signaling are of great clinical interest. signaling, however, multifaceted and variable among tissues, developmental disease entities. Hence, targeted biomarkers pathways prime importance research. We developed a novel real-time qPCR-based array. Only mechanistically validated targets were included. then used random-forest classification to define...
Four cycles of rituximab plus CHOP chemotherapy is as effective 6 in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis prospective clinical trial patients with HIV-associated DLBCL and high-grade treated 4–6 EPOCH based response-adapted treatment strategy. 106 evaluable or CD20-positive non-Hodgkin's were randomized to receive (375 mg/m2) given either concurrently prior each infusional cycle, sequentially (weekly for weeks) following completion EPOCH....
Kaposi's sarcoma (KS) is a multifocal low-grade vascular neoplasm that can affect the skin, mucus membranes, visceral organs, and lymph nodes. KS also ocular surface adnexa masquerade as other entities, delaying prompt diagnosis.In this review, manifestations of are discussed along with theories for pathogenesis, common risk factors, management options.KS caused by oncogenic human herpesvirus 8 (HHV8). Immunosuppression in patients HIV AIDS contributes to development but conjunctival adnexal...
HIV-associated lymphomas (HALs) have high rates of latent infection by gammaherpesviruses (GHVs). We hypothesized that proteasome inhibition would induce lytic activation GHVs and inhibit HIV infectivity via preservation cytidine deaminase APOBEC3G, improving lymphoma control. tested this oncolytic antiviral strategy using bortezomib combined with ifosfamide, carboplatin, etoposide (ICE) alone or rituximab (ICE/R) in relapsed/refractory HAL. A 3+3 dose-escalation design was used a 7-day...